



ASX ANNOUNCEMENT

Simavita releases ASX Appendix 4C for the quarter ended March 31, 2018

For Immediate Release:

April 30, 2018

Sydney, Australia – Simavita Limited (ASX: SVA) today reported its March 31, 2018 quarter end results. The Appendix 4C is being re-lodged to correct an error in one of the cash balance figures.

- **Simavita ended the quarter for the period to March 31, 2018 with cash reserves of AUD\$850,000.**
- **Convertible notes totalling \$1.4m before costs, as announced on March 15, 2018 and approved at the Special General Meeting held on April 13, 2018, will be issued in early May 2018.**
- **In line with the Company's PIVOT strategy, Simavita has developed, manufactured and patented, a hyper low cost platform technology. AlertPLUS™ is focused upon a rapidly growing USD21bn per year, adult and infant diaper industry. The Company continues to progress licensing discussions with several major international diaper manufacturers based in North America and Europe. AlertPLUS™ from Simavita delivers:**
 - **A hyper low cost sensor, inserted into all diapers at the time of manufacture**
 - **Automatic detection of wetness events and an alert for carers via a smart device, phone or tablet**
 - **A continuous innovation platform in health care for the aged, disabled and infant markets**
 - **A truly disruptive technology that materially reduces the work load of carers whilst transforming the product delivered by the global diaper industry.**

The Company in the short term will continue to look toward shareholder support to fund operations and to meet its business objectives. Based upon Simavita's key PIVOT business strategy, the Company is working hard to rapidly transition to a profitable and valuable business.

The Company's sales strategy is to license our AlertPLUS™ platform technology to major manufacturers and to partner AssessPLUS™ with large and successful businesses who have synergistic products and commitment.

- **Simavita continues to tightly manage ongoing operating costs with total cash outflows for the quarter of \$1.39, down 16% from the previous quarter of \$1.66m. Forecast cash outflows for the coming quarter are \$1.38m.**
- **The Company confirms that it continues to be in compliance with Listing Rules 3.1 and 12.2.**

For further information, please view our website (www.simavita.com) or contact:

Ms Peta Jurd
Chief Commercial Officer

E: pjurd@simavita.com
T: +61 421 466 653
W: Investor Centre: [Click here](#)

About Simavita

Simavita (ASX: SVA) develops and markets advanced systems associated with smart, wearable and disposable sensors for the health care industry. Our first products focus on major unmet needs for the assessment and management of incontinence. The annual global economic burden is billions of dollars for incontinence diapers alone and is increasing rapidly.

Simavita operates in Australia, Europe and North America where there is a significant and growing demand for products that deliver real clinical and cost benefits to the health care industry.

With the support of our shareholders, customers and employees, Simavita is absolutely committed to the business at hand; creating a commercially successful and growing corporation. www.simavita.com

Forward-Looking Information

This document may contain “forward-looking information” within the meaning of Canadian securities laws (“forward-looking information”). This forward-looking information is given as of the date of this document.

Forward-looking information relates to future events or future performance and reflects Simavita management’s expectations or beliefs regarding future events. Assumptions upon which such forward-looking information is based include that Simavita will be able to successfully execute on its business plans. Many of these assumptions are based on factors and events that are not within the control of Simavita and there is no assurance they will prove to be correct.

In certain cases, forward-looking information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “potential”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or information that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved” or the negative of these terms or comparable terminology. By its very nature forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Simavita to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Such factors include, among others, risks related to actual results of current business activities; changes in business plans and strategy as plans continue to be refined; other risks of the medical devices and technology industry; delays in obtaining governmental approvals or financing or in the completion of development activities; as well as those factors detailed from time to time in Simavita’s interim and annual financial statements and management’s discussion and analysis of those statements. Although Simavita has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. Simavita provides no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking information